Navigation Links
Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
Date:9/24/2007

HAMBURG, Germany and OXFORD, England, September 24 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that Jorn Aldag, President & CEO, and Dr John Kemp, Chief Research & Development Officer, will present at the UBS 2007 Global Life Sciences Conference at 03.30 pm EST (09.30 pm CET/08.30 pm BST) on Wednesday, 26 September 2007, at Grand Hyatt, New York City. During the presentation management will provide an overview of its recently announced agreement to acquire Renovis, Inc.

The company presentation will be webcast live and will be accessible through the Evotec website at http://www.evotec.com - Investors. A replay will also be available at http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

http://www.evotec.com

Forward looking statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the anticipated timing and results of Evotec's clinical and preclinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information as a result of risks and uncertainties relating to: the need to adapt to significant technological change; use and protection of intellectual property; as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. Evotec expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties' expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49-(0)40-56081-286

Fax: +49-(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , ... January 12, 2017 , ... Each year, Crain’s ... Index – a process that evaluates the patent estate of a company, its impact ... , a biomedical firm leading the way in technologies that transform energy sources such ...
(Date:1/12/2017)... AURORA, Colo (PRWEB) , ... January 12, 2017 ... ... and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a ... eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased ...
(Date:1/12/2017)... January 12, 2017 A new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro toxicity ... at a CAGR of 15.07% during the forecast period. ... ... ...
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
Breaking Biology Technology:
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
Breaking Biology News(10 mins):